Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference - Century Therapeutics (NASDAQ:IPSC)

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.

Realty Income (NYSE: O) says it began investing in data centers in late 2023 via a build-to-suit JV with Digital Realty, buying an 80% stake in an up to 48 MW facility. It also formed a hyperscale JV with Cloud Capital, targeting up to $1.4B investment for a 45% stake. Realty Income raised 2024 AFFO guidance to $4.44-$4.45/share and investment outlook to $10B.

Bloomberg reported the US Army plans to buy at least $400 million of AeroVironment counter-drone laser systems, citing a person familiar with the deal. The order would include dozens of LOCUST units that use AI to detect and track small to medium drones and then engage them with a high-energy laser. AeroVironment’s stock rose about 8% on Friday.